Browsing by Author "Molgo, Montserrat"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey
    (2023) Quaglino, Pietro; Scarisbrick, Julia; Roccuzzo, Gabriele; Abeldano, Alejandra; Battistella, Maxime; McCormack, Chris; Cowan, Richard; Cozzio, Antonio; Cury-Martins, Jade; Enz, Paula; Geskin, Larisa; Guenova, Emmanuella; Kim, Youn H.; Knobler, Robert; Litvinov, Ivan V.; Miyagaki, Tomomitsu; Molgo, Montserrat; Nicolay, Jan; Papadavid, Evangelina; Pinter-Brown, Lauren; Pujol Vallverdu, Ramon; Querfeld, Christiane; Ortiz-Romero, Pablo; Stadler, Rudolf; Vermeer, Maarten H.; Bagot, Martine; Hodak, Emmilia
    Background Consensus about the definition and classification of 'plaque' in mycosis fungoides is lacking. ObjectivesTo delineate a comprehensive view on how the 'plaque' entity is defined and managed in clinical practice; to evaluate whether the current positioning of plaques in the TNMB classification is adequate. MethodsA 12-item survey was circulated within a selected panel of 22 experts (pathologists, dermatologists, haematologists and oncologists), members of the EORTC and International Society for Cutaneous Lymphoma. The questionnaire discussed clinical and histopathological definitions of plaques and its relationship with staging and treatment. Results Total consensus and very high agreement rates were reached in 33.3% of questions, as all panellists regularly check for the presence of plaques, agree to evaluate the presence of plaques as a potential separate T class, and concur on the important distinction between plaque and patch for the management of early-stage MF. High agreement was reached in 41.7% of questions, since more than 50% of the responders use Olsen's definition of plaque, recommend the distinction between thin/thick plaques, and agree on performing a biopsy on the most infiltrated/indurated lesion. High divergence rates (25%) were reported regarding the possibility of a clinically based distinction between thin and thick plaques and the role of histopathology to plaque definition. ConclusionsThe definition of 'plaque' is commonly perceived as a clinical entity and its integration with histopathological features is generally reserved to specific cases. To date, no consensus is achieved as for the exact definition of thin and thick plaques and current positioning of plaques within the TNMB system is considered clinically inadequate. Prospective studies evaluating the role of histopathological parameters and other biomarkers, as well as promising diagnostic tools, such as US/RM imaging and high-throughput blood sequencing, are much needed to fully integrate current clinical definitions with more objective parameters.
  • Thumbnail Image
    Item
    Leukocytoclastic Vasculitis as Early Manifestation of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma of the Elderly
    (LIPPINCOTT WILLIAMS & WILKINS, 2012) Zoroquiain, Pablo; Gonzalez, Sergio; Molgo, Montserrat; Rodriguez, Alejandra; Valbuena, Jose R.
    Extensive necrotizing vasculitis (ENV) is a rare paraneoplastic phenomenon, and the majority of cases reported are associated with hematolymphoid neoplasms. Histologically, most cases of ENV represent leukocytoclastic vasculitis (LCV). Here we report the clinicopahological features of a 68-year-old man with ENV associated to a Epstein Barr virus-positive diffuse large B-cell lymphoma (EBV+DLBCL) of the elderly, a newly recognized lymphoproliferative disorder, most likely representing a paraneoplastic manifestation. The patient was treated with standard chemotherapy regimen for malignant lymphoma. Due to the extensive involvement of the extremities by ENV, surgical debridement was not feasible and a novel therapy based on CHITOSAN apposits was initiated with overall good response and subsequent re-epithelization of the skin lesions. The patient died of sepsis secondary to a Pseudomona pneumonia 17 months after diagnosis.
  • Thumbnail Image
    Item
    Tanning salons in Santiago, Chile: the knowledge of the staff in charge and the quality of information provided to potential clients before and after a new regulatory law
    (WILEY-BLACKWELL PUBLISHING, INC, 2009) Salomone, Claudia; Majerson, Daniela; Molgo, Montserrat; Maria, Maria Luisa Saenz de Santa; Romero, William
    In recent years, the use of artificial tanning devices has become very popular in Chile. In April, 2007, a new law was established to regulate the non-medical use of tanning beds and tanning booths. The aim of this study was to evaluate the level and quality of information provided by tanning salon staff to clients before deciding on using the services. This information was collected before and 6 months after the law was enacted by researchers visiting tanning salons posing as potential clients.
  • No Thumbnail Available
    Item
    Taxane-induced scleroderma. Report of two cases
    (2021) Cury-Martins, Jade; Giesen, Laura; Gonzalez, Sergio; Molgo, Montserrat; Antonio Sanches, Jose
    Taxanes are a class of chemotherapeutic agents with common associated dermatologic adverse events, such as skin hyperpigmentation, hand-foot skin syndrome, paronychia and onycholysis. Taxane-induced scleroderma is rare. Few cases with skin findings resembling systemic sclerosis, have been reported after the administration of these agents. We report two cases with stage IV breast cancer, aged 66 and 71 years, who developed sclerodermic skin lesions in their extremities after starting treatment with placlitaxel and nabplaclitaxel respectively.
  • No Thumbnail Available
    Item
    Understanding current therapies in metastatic melanoma
    (SOC MEDICA SANTIAGO, 2016) Rodriguez, Rocio; Para, Angela; Gonzalez, Sergio; Molgo, Montserrat; Droppelmann, Nicolas; Acevedo, Francisco; Pena, Jose; Uribe, Pablo
    Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen- 4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-L1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PD-L1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.